Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.
Kelly WK, et al. Among authors: tong w.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88.
Clin Cancer Res. 2003.
PMID: 14506144
Clinical Trial.